Royalty Pharma’s $2 billion IPO target shows importance of patent monetisation in life sciences
The company’s public offering comes after years of growth and demonstrates the changing dynamics of an industry in which smaller R&D entities are becoming increasingly significant players
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.